Celcuity gains; J.P.Morgan initiates coverage with 'overweight'

By Reuters News

** U.S. biotechnology firm Celcuity CELC.O shares rise 2.3% to $84.50 in premarket trading

** J.P.Morgan initiates coverage with "overweight" rating; PT $157
** Says rating "driven by the long-term potential of Revtorpyk in breast cancer"

** Adds that "we see several long-term upside levers in the model, including Revtorpyk penetration/ramp in the 2L (second-line treatment) setting, potential in the front-line setting, and potential indication expansion."

** Co posted narrower-than-expected loss in Q2

** Up to last day's close, shares down 17.2% YTD

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
 

Cryptocurrency-related content is intended solely as news and market commentary. Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd.